Kate Bosworth Partners with Allergan to Celebrate Launch of ACZONE® (dapsone) Gel, 7.5% in New York City

"While one of my favorite parts of the job is being able to travel the world, my on-the-go schedule can encounter several inconsistencies, like lack of sleep or environmental changes," Kate says.^3,4 "Finding a balance with a healthy lifestyle and consistent skin care regimen has helped me tremendously. I visited my dermatologist and was prescribed ACZONE^® Gel, 7.5% to treat my acne."

Acne affects 40 to 50 million men and women in the U.S. alone, and nearly 85% of people between the ages of 12 and 24 struggle with acne at some point in their lives.² Even though acne is more common in teenagers, adult acne may be more common than previously thought; about one out of three people seeking treatment for acne are 25 years or older.^5,6 Acne is a multifactorial disease—environmental factors, hormonal fluctuations, medications, heredity/genetics, emotional stress and diet may all contribute to acne.²  

"We are very fortunate to be partnering with Kate for this event to launch the new ACZONE® Gel, 7.5%," says Jag Dosanjh, Senior Vice President, Medical Dermatology at Allergan. "Through Kate's story, we hope to show acne sufferers that they are not alone with acne on their mind and encourage them to visit a dermatologist to find the right treatment option and help have less acne to think about."

"It is not uncommon for women to develop acne for the first time as an adult, in their 20s or 30s.⁷ I always remind my patients that acne is not just an issue teenagers suffer with.  While there is no cure, it can be managed with the right treatment regimen," said Joshua Zeichner, NYC-based Dermatologist. "ACZONE® Gel, 7.5% was approved by the U.S. Food and Drug Administration (FDA) in February 2016. In the largest pivotal trial program conducted for FDA approval of a topical acne drug, once-daily application ACZONE® Gel, 7.5% was clinically proven to be effective and safe in treating inflammatory and comedonal acne in 12 weeks." ¹

For more information or to find a dermatologist, please visit www.aczone.com.

PHOTO CAPTION: Actress, Producer and Model Kate Bosworth at the ACZONE^® (dapsone) Gel, 7.5% Launch Event in New York City

PHOTO CREDIT: Jennifer Graylock, Getty Images

Approved Use

ACZONE^® (dapsone) Gel, 7.5% is a prescription medicine used on the skin (topical) to treat acne in people 12 years and older.

Important Safety Information

Tell your doctor about all of your medical conditions, including if you have; glucose-6-phosphate dehydrogenase deficiency (G6PD) or higher than normal levels of methemoglobin in your blood (methemoglobinemia).

Talk to your doctor about any medications you're using including topical benzoyl peroxide (BPO). Use of BPO with ACZONE^® Gel may cause your skin and facial hair to temporarily turn yellow or orange at the site of application.

ACZONE^® Gel, 7.5% may cause serious side effects, including:

• a decrease of oxygen in your blood caused by a certain type of abnormal red blood cell (methemoglobinemia).  If your lips, nail beds or the inside of your mouth turns grey or blue, stop using ACZONE^® Gel, 7.5% and get medical help right away.
• a breakdown of red blood cells (hemolytic anemia) for some people with G6PD deficiency using ACZONE^® Gel, 7.5%. Stop using ACZONE^® Gel, 7.5%, and call your doctor right away if you get any of the following signs and symptoms: back pain, breathlessness, tiredness/weakness, dark-brown urine, fever, or yellow or pale skin.

The most common side effects of ACZONE^® Gel, 7.5% are dryness and itching of the skin being treated.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for the full Product Information.

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. 

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

¹ ACZONE® (dapsone) Gel 7.5% U.S. Prescribing Information

² American Academy of Dermatology. "Acne." Available online at: https://www.aad.org/media/stats/conditions Last accessed on April 28, 2016

³ Glozier, N. et al. Short Sleep Duration in Prevalent and Persistent Psychological Distress in Young Adults: The DRIVE Study, 2010; 33 (9); 1139-1145

⁴ American Academy of Dermatology, "Adult acne." Available online at: https://www.aad.org/public/diseases/acne-and-rosacea/adult-acne  Last accessed on December 7, 2015

⁵ American Academy of Dermatology. Acne: who gets and causes. Available at: https://www.aad.org/public/diseases/acne-and-rosacea/acne. Accessed January 19, 2016.

⁶ Yentzer BA, Hick J, Reese EL, Uhas A, Feldman SR, Balkrishnan R. Acne vulgaris in the United States: a descriptive epidemiology. Cutis. 2010;86(2):94–99.

⁷ American Academy of Dermatology. "Acne and Rosacea." Last updated June 8, 2011

APC45VP16

CONTACTS:     

Media: 
Mark Marmur
(973) 906-1526

Ember Garrett
(714) 246-3525

Photo - http://photos.prnewswire.com/prnh/20160605/375614 
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

SOURCE Allergan plc

Related Links

http://www.allergan.com